GAITHERSBURG, Md., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:
| 2020 BIO CEO & Investor Conference | |
| Date: | Monday, February 10 |
| Time: | 10:45am ET |
| Title: | Altimmune, Inc. Overview |
| Speaker: | Vipin K. Garg Ph. D., President and Chief Executive Officer |
| Location: | New York Marriott Marquis, New York, NY |
| Webcast: | https://ir.altimmune.com/investors/events-and-presentations |
| The 3rd Global NASH Conference | |
| Date: | Tuesday, February 11 |
| Time: | 11:55 am GMT / 6:55 am ET |
| Title: | Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH |
| Speaker: | M. Scott Harris M.D., Chief Medical Officer |
| Location: | The London Heathrow Marriott Hotel, London, UK |
| Presentation: | https://ir.altimmune.com/investors/events-and-presentations |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company's diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShield™ and NasoVAX™). For more information on Altimmune, please visit www.altimmune.com.
| Contacts | ||
| Will Brown | Ashley R. Robinson | |
| Chief Financial Officer | Managing Director LifeSci Advisors | |
| Phone: 240-654-1450 | Phone: 617-535-7742 | |
| Email: wbrown@altimmune.com | Email: arr@lifesciadvisors.com |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
